<?xml version="1.0" encoding="UTF-8"?>
<p>13. The authors report that “HIV coinfection was noted in 14% of HBsAg-positive individuals and the majority were taking tenofovir-containing antiretroviral therapy (ART).” If this is indeed the case, then what are the ramifications for HBV treatment programs in Africa? In resource-poor settings with overlapping HIV and HBV epidemics one could embed HBV elimination programs in running HIV programs. This should be addressed in brief in the discussion.</p>
